Align Technology, Inc. has entered into an accelerated stock repurchase agreement (ASR) with Goldman Sachs & Co. LLC to repurchase $270 million of its common stock. This agreement is part of Align's broader $1 billion stock repurchase program, which was approved by the company’s Board of Directors in April 2025. The move is significant as it demonstrates Align's commitment to returning capital to its shareholders while maintaining a strong financial position.

Align Technology, based in Tempe, Arizona, is a leading global medical device company specializing in the design and manufacture of the Invisalign System, iTero intraoral scanners, and exocad CAD/CAM software. The company operates under the SIC code 3842, which pertains to orthopedic, prosthetic, and surgical appliances and supplies. Align is listed on the Nasdaq under the ticker symbol ALGN.

According to the SEC filing dated November 5, 2026, the ASR Contract allows Align to make a $270 million prepayment to Goldman Sachs, receiving an initial delivery of approximately 1.44 million shares of its common stock. The final number of shares repurchased will depend on the average daily volume-weighted price of Align’s stock during the repurchase period, minus a discount. The transaction is expected to settle by December 29, 2026.

This stock repurchase agreement may affect various stakeholders, including shareholders who will benefit from the reduced share count and potential increase in earnings per share. The filing indicates that the remaining balance for future repurchases under the $1 billion program will be approximately $330 million after this transaction.

Align Technology plans to issue a press release on November 6, 2026, to announce the details of the ASR Contract. This strategic move aligns with the company’s long-term vision and reflects its confidence in sustained growth and innovation within the orthopedic and surgical appliance industry.